Development of Neutralizing Antibodies in Patients with Relapsing-Remitting Multiple Sclerosis Treated with IFN-??1a, Journal of Interferon & Cytokine Research, vol.18, issue.5, p.345, 1998. ,
DOI : 10.1089/jir.1998.18.345
Reduced effectiveness of long-term interferon-?? treatment on relapses in neutralizing antibody-positive multiple sclerosis patients: a Canadian multiple sclerosis clinic-based study, Multiple Sclerosis Journal, vol.48, issue.1, p.1127, 2007. ,
DOI : 10.1191/1352458504ms1004oa
A randomized, double-blind, dose-comparison study of weekly interferon ??-1a in relapsing MS, European IFNbeta-1a (Avonex) Dose-Comparison Study Investigators, p.1507, 2002. ,
DOI : 10.1212/01.WNL.0000032256.35561.D6
Benefit of interferon ??-1a on MSFC progression in secondary progressive MS, IMPACT Investigators, p.679, 2002. ,
DOI : 10.1212/WNL.59.5.679
Multiple sclerosis, Lancet, vol.359, 1221. ,
URL : https://hal.archives-ouvertes.fr/hal-00996686
A Novel Sensitive and Selective Bioassay for Human Type I Interferons, Journal of Interferon & Cytokine Research, vol.18, issue.12, 1019. ,
DOI : 10.1089/jir.1998.18.1019
The Neutralization of Interferons by Antibody. II. Neutralizing Antibody Unitage and Its Relationship to Bioassay Sensitivity: The Tenfold Reduction Unit, Journal of Interferon & Cytokine Research, vol.21, issue.9, p.743, 2001. ,
DOI : 10.1089/107999001753124471
Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis, Annals of Neurology, vol.43, issue.3, p.285, 1996. ,
DOI : 10.1002/ana.410390304
Intramuscular Interferon Beta-1A Therapy Initiated during a First Demyelinating Event in Multiple Sclerosis, New England Journal of Medicine, vol.343, issue.13, p.898, 2000. ,
DOI : 10.1056/NEJM200009283431301
Validating parameters of a luciferase reporter gene assay to measure neutralizingantibodies to IFN beta in multiple sclerosis patients, J. Immunol. Methods, vol.336, issue.113, 2008. ,
A novel bioassay for the determination of neutralizing antibodies to IFN-beta1b, J. Interferon Cytokine Res, vol.18, 1025. ,
Bioequivalence and the immunogenicity of biopharmaceuticals, Nature Reviews Drug Discovery, vol.1, issue.6, p.457, 2002. ,
DOI : 10.1038/nrd818
Domains of Interaction between Alpha Interferon and its Receptor Components, Journal of Molecular Biology, vol.243, issue.2, p.245, 1994. ,
DOI : 10.1006/jmbi.1994.1651
The scatter plot for logarithm of NAb titers measured by luciferase (UBC) vs. CPE (Iran) Titers are expressed in log10. Spearman coefficient r=0 ,